Rani Bansal

Featured in: Favicon

nature.com Favicon

cancernetwork.com Favicon

ajts.org

Articles

Blood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers - Communications Medicine

Dec 2, 2024 | nature.com | Pingfu Fu |Rani Bansal |Leslie A. Bucheit

AbstractBreast and prostate tumors are known to be less responsive to immune checkpoint inhibitors (ICIs). Tissue-based tumor mutation burden (tTMB) has emerged as a predictive biomarker of response to ICIs, including in these “cold tumors”.
Radiation Necrosis with ADCs and Concurrent Radiotherapy for Brain Metastases

Mar 1, 2024 | cancernetwork.com | Carey Anders |Heather Moore |Rani Bansal |Susan Dent

2 Commerce Drive Cranbury, NJ 08512
Patient Case Presentation: A 34-Year-Old Woman with HER+ mBC and Brain Metastases

Feb 23, 2024 | cancernetwork.com | Carey Anders |Heather Moore |Rani Bansal |Susan Dent

2 Commerce Drive Cranbury, NJ 08512
BRIDGET: Preventing Secondary Brain Metastases in Advanced HER2+ Breast Cancer

Feb 16, 2024 | cancernetwork.com | Carey Anders |Heather Moore |Rani Bansal |Susan Dent

2 Commerce Drive Cranbury, NJ 08512
Patient Case Presentation: A 34-Year-Old Woman with HER2+ mBC and Brain Metastases

Feb 16, 2024 | cancernetwork.com | Carey Anders |Heather Moore |Rani Bansal |Susan Dent

2 Commerce Drive Cranbury, NJ 08512
HER2CLIMB: Targeting Stable and Active Brain Metastases in Advanced HER2+ Breast Cancer

Feb 16, 2024 | cancernetwork.com | Carey Anders |Heather Moore |Rani Bansal |Susan Dent

2 Commerce Drive Cranbury, NJ 08512
Treatment Approaches for Triple-Positive mBC in the 2L Setting and Beyond

Feb 9, 2024 | cancernetwork.com | Carey Anders |Heather Moore |Rani Bansal |Susan Dent

2 Commerce Drive Cranbury, NJ 08512
The Role of Radiotherapy in HER2+ mBC

Feb 9, 2024 | cancernetwork.com | Carey Anders |Heather Moore |Rani Bansal |Susan Dent

2 Commerce Drive Cranbury, NJ 08512
Approaches for 1L Therapy and Restaging in Triple-Positive mBC

Jan 5, 2024 | cancernetwork.com | Carey Anders |Heather Moore |Rani Bansal |Susan Dent

Approaches for 1L Therapy and Restaging in Triple-Positive mBCSusan Dent, MD, delves into the exploration of front-line treatment options for triple-positive breast cancer and examines strategies for restaging in the event of disease progression after first-line therapy.
Advancements in Treatment Strategies for HER2+ Metastatic Breast Cancer: Insights from Experts at the Duke Cancer Center

Dec 17, 2023 | cancernetwork.com | Carey Anders |Heather Moore |Rani Bansal |Susan Dent

Advancements in Treatment Strategies for HER2+ Metastatic Breast Cancer: Insights from Experts at the Duke Cancer CenterIn this Cancer Network Around the Practice program, Susan Dent, MD discusses the case of a 66-year-old patient with grade 3 triple-positive breast cancer who presents with multiple liver and bone metastases after front-line treatment with trastuzumab and letrozole.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

Rani Bansal

Articles

Blood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers - Communications Medicine

Radiation Necrosis with ADCs and Concurrent Radiotherapy for Brain Metastases

Patient Case Presentation: A 34-Year-Old Woman with HER+ mBC and Brain Metastases

BRIDGET: Preventing Secondary Brain Metastases in Advanced HER2+ Breast Cancer

Patient Case Presentation: A 34-Year-Old Woman with HER2+ mBC and Brain Metastases

HER2CLIMB: Targeting Stable and Active Brain Metastases in Advanced HER2+ Breast Cancer

Treatment Approaches for Triple-Positive mBC in the 2L Setting and Beyond

The Role of Radiotherapy in HER2+ mBC

Approaches for 1L Therapy and Restaging in Triple-Positive mBC

Advancements in Treatment Strategies for HER2+ Metastatic Breast Cancer: Insights from Experts at the Duke Cancer Center

Contact details

Emails

Socials & Sites